Shots:
- The US FDA has approved Ctexli (chenodiol) to treat cerebrotendinous xanthomatosis (CTX) in adults
- Efficacy was established in crossover withdrawal P-III (RESTORE) trial assessing Ctexli (250mg, PO, TID) vs PBO in pts for 24wks.
- Study showed reduced levels of plasma cholestanol & urine 23S-pentol in pts compared to PBO
Ref: Prnewswire | Image: Mirum
Related News:- Mirum Pharmaceuticals’ Livmarli Receives the EC’s Approval to Treat Progressive Familial Intrahepatic Cholestasis (PFIC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
